Plunkett W - Search Results

1

Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study.

Grunewald R, Kantarjian H, Du M, Faucher K, Tarassoff P, Plunkett W. Grunewald R, et al. Among authors: plunkett w. J Clin Oncol. 1992 Mar;10(3):406-13. doi: 10.1200/JCO.1992.10.3.406. J Clin Oncol. 1992. PMID: 1740680 Clinical Trial.

2

Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia.

Gandhi V, Plunkett W, Du M, Ayres M, Estey EH. Gandhi V, et al. Among authors: plunkett w. J Clin Oncol. 2002 Feb 1;20(3):665-73. doi: 10.1200/JCO.2002.20.3.665. J Clin Oncol. 2002. PMID: 11821446 Clinical Trial.

3

Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.

Kantarjian HM, Gandhi V, Kozuch P, Faderl S, Giles F, Cortes J, O'Brien S, Ibrahim N, Khuri F, Du M, Rios MB, Jeha S, McLaughlin P, Plunkett W, Keating M. Kantarjian HM, et al. Among authors: plunkett w. J Clin Oncol. 2003 Mar 15;21(6):1167-73. doi: 10.1200/JCO.2003.04.031. J Clin Oncol. 2003. PMID: 12637486 Clinical Trial.

4

Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias.

Gandhi V, Kantarjian H, Faderl S, Bonate P, Du M, Ayres M, Rios MB, Keating MJ, Plunkett W. Gandhi V, et al. Among authors: plunkett w. Clin Cancer Res. 2003 Dec 15;9(17):6335-42. Clin Cancer Res. 2003. PMID: 14695132 Clinical Trial.

5

Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome.

Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, Westwood R, Green SR, Chiao JH, Boone PA, Cortes J, Plunkett W. Kantarjian H, et al. Among authors: plunkett w. J Clin Oncol. 2010 Jan 10;28(2):285-91. doi: 10.1200/JCO.2009.25.0209. Epub 2009 Nov 23. J Clin Oncol. 2010. PMID: 19933907 Free PMC article. Clinical Trial.

6

Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine.

Grunewald R, Abbruzzese JL, Tarassoff P, Plunkett W. Grunewald R, et al. Among authors: plunkett w. Cancer Chemother Pharmacol. 1991;27(4):258-62. doi: 10.1007/BF00685109. Cancer Chemother Pharmacol. 1991. PMID: 1998982 Clinical Trial.

7

Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia.

Grunewald R, Kantarjian H, Keating MJ, Abbruzzese J, Tarassoff P, Plunkett W. Grunewald R, et al. Among authors: plunkett w. Cancer Res. 1990 Nov 1;50(21):6823-6. Cancer Res. 1990. PMID: 2208147

8

Gemcitabine: metabolism, mechanisms of action, and self-potentiation.

Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Plunkett W, et al. Semin Oncol. 1995 Aug;22(4 Suppl 11):3-10. Semin Oncol. 1995. PMID: 7481842 Review.

9

Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia.

Gandhi V, Plunkett W, Kantarjian H, Talpaz M, Robertson LE, O'Brien S. Gandhi V, et al. Among authors: plunkett w. J Clin Oncol. 1998 Jul;16(7):2321-31. doi: 10.1200/JCO.1998.16.7.2321. J Clin Oncol. 1998. PMID: 9667246 Clinical Trial.

10

Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.

Gandhi V, Estey E, Du M, Keating MJ, Plunkett W. Gandhi V, et al. Among authors: plunkett w. Clin Cancer Res. 1997 Sep;3(9):1539-45. Clin Cancer Res. 1997. PMID: 9815841

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

320 results

Search Page

Filters